Literature DB >> 16392774

Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine.

Hiroe Toba1, Yoshitsugu Nakagawa, Shunsuke Miki, Takahiro Shimizu, Akiko Yoshimura, Riyako Inoue, Jun Asayama, Miyuki Kobara, Tetsuo Nakata.   

Abstract

Long-acting dihydropyridine calcium channel blockades have been shown to limit the progression of atherosclerosis and decrease the incidence of cardiovascular events in humans and animals. To investigate the vasoprotective effects beyond the blood pressure-lowering effects of these agents, amlodipine (20 mg/kg/ day) and manidipine (10 mg/kg/day) were administered by gavage to N(G)-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rats for 2 weeks. L-NAME treatment (0.7 mg/ml in drinking water) significantly decreased the gene and protein expression of endothelial nitric oxide synthase (eNOS) and increased nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, vascular cell adhesion molecule-1 (VCAM-1), and monocyte chemoattractant protein-1 (MCP-1) mRNA levels in the aorta, as determined by Western blotting and reverse transcription (RT)-polymerase chain reaction (PCR). Amlodipine and manidipine normalized the decreased expression of eNOS gene and protein, and attenuated the overexpression of NADPH oxidase, VCAM-1, and MCP-1 mRNA. Furthermore, amlodipine and manidipine prevented the L-NAME-induced increase in the angiotensin converting enzyme (ACE) mRNA content, thereby restoring control levels in the aorta. On the other hand, hydralazine treatment had no such effect in L-NAME treated rats. Furthermore, the increased expression of manganese superoxide dismutase (Mn-SOD) by L-NAME treatment was not affected by amlodipine, manidipine, or hydralazine. We concluded that the direct anti-inflammatory and antioxidative effects of calcium channel blockades in the aorta of rats with L-NAME-induced hypertension were not likely to have been mediated by the blood pressure-lowering action of these agents, but instead these beneficial effects appear to have been mediated by an augmentation of eNOS expression and by the inhibition of the expression of ACE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16392774     DOI: 10.1291/hypres.28.689

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  13 in total

1.  Increased leukocyte Rho-associated coiled-coil containing protein kinase activity predicts the presence and severity of coronary vasospastic angina.

Authors:  Ming-Jui Hung; Wen-Jin Cherng; Ming-Yow Hung; Li-Tang Kuo; Chi-Wen Cheng; Chao-Hung Wang; Ning-I Yang; James K Liao
Journal:  Atherosclerosis       Date:  2012-01-12       Impact factor: 5.162

Review 2.  Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.

Authors:  Kirtiman Srivastava; Philip M W Bath; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2011-12-25       Impact factor: 5.046

3.  Syringic acid ameliorates (L)-NAME-induced hypertension by reducing oxidative stress.

Authors:  Subramanian Kumar; Pichavaram Prahalathan; Boobalan Raja
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-19       Impact factor: 3.000

Review 4.  Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research.

Authors:  Augusto C Montezano; Rhian M Touyz
Journal:  Antioxid Redox Signal       Date:  2013-06-06       Impact factor: 8.401

Review 5.  Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide?

Authors:  Thor Tejada; Alessia Fornoni; Oliver Lenz; Barry J Materson
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

Review 6.  Hypertension: a new treatment for an old disease? Targeting the immune system.

Authors:  Gisele Facholi Bomfim; Stefany Bruno Assis Cau; Alexandre Santos Bruno; Aline Garcia Fedoce; Fernando S Carneiro
Journal:  Br J Pharmacol       Date:  2018-07-31       Impact factor: 8.739

7.  Time course of cardiac inflammation during nitric oxide synthase inhibition in SHR: impact of prior transient ACE inhibition.

Authors:  Lauren A Biwer; Karen M D'souza; Ali Abidali; Danni Tu; Ashley L Siniard; Matthew DeBoth; Matthew Huentelman; Taben M Hale
Journal:  Hypertens Res       Date:  2015-10-22       Impact factor: 3.872

8.  Altered expression of sodium transporters and water channels in the submandibular gland of rats treated with nitric oxide synthesis inhibitors.

Authors:  Il-Young Seo; Miwon Kim; Jongun Lee; Sun-Youl Ryu
Journal:  Electrolyte Blood Press       Date:  2008-06-30

9.  Mechanisms of the antihypertensive effects of Nigella sativa oil in L-NAME-induced hypertensive rats.

Authors:  Kamsiah Jaarin; Wai Dic Foong; Min Hui Yeoh; Zaman Yusoff Nik Kamarul; Haji Mohd Saad Qodriyah; Abdullah Azman; Japar Sidik Fadhlullah Zuhair; Abdul Hamid Juliana; Yusof Kamisah
Journal:  Clinics (Sao Paulo)       Date:  2015-11       Impact factor: 2.365

10.  Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes.

Authors:  Hassan Fares; James J DiNicolantonio; James H O'Keefe; Carl J Lavie
Journal:  Open Heart       Date:  2016-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.